CAI Dongchen (Chairman)
Mr. Cai, Chairman of the Company, was appointed as an executive director of the Company in 1998. Mr. Cai is also the chairman of the Nomination Committee of the Company and a director of certain subsidiaries of the Group. Mr. Cai holds an MBA degree from Nankai University and has extensive technical and management experience in the pharmaceutical industry.

ZHANG Cuilong (Vice Chairman and CEO)
Mr. Zhang, Vice-Chairman and Chief Executive Officer of the Company, was appointed as an executive director of the Company in 2018. Mr. Zhang is also a director of certain subsidiaries of the Group. Mr. Zhang holds a bachelor’s degree in pharmacology from Hebei Medical College (now known as Hebei Medical University) and has extensive technical, marketing and management experience in the pharmaceutical industry.

PAN Weidong
Mr. Pan was appointed as an executive director of the Company in 2006. Mr. Pan is also a director of certain subsidiaries of the Group. Mr. Pan holds an EMBA degree from Tsinghua University and has extensive finance, accounting and investment experience in the pharmaceutical industry.

WANG Zhenguo
Mr. Wang was appointed as an executive director of the Company in 2012. Mr. Wang is also a director of certain subsidiaries of the Group. Mr. Wang holds a bachelor’s degree in chemistry from Nankai University and has extensive technical, marketing and management experience in the pharmaceutical industry.

WANG Huaiyu
Mr. Wang was appointed as an executive director of the Company in 2010. Mr. Wang is also a director of certain subsidiaries of the Group. Mr. Wang holds a bachelor’s degree in microbiology and biochemistry from Hebei University and has extensive technical and management experience in the pharmaceutical industry.

LI Chunlei
Dr. Li was appointed as an executive director of the Company in 2017. Dr. Li is currently the Chief Scientist of the Group in charge of research and development. Dr. Li is also the general manager of a subsidiary of the Company, deputy director of the Novel Pharmaceutical Preparations and Excipients State Key Laboratory and director of the Hebei Pharmaceutical Engineering Technology Centre. Dr. Li holds a bachelor’s degree in engineering (biological pharmaceutics) from Jilin University and Shenyang Pharmaceutical University, a master’s degree in science (microbial and biochemical pharmaceutics) from Jilin University and a doctorate in science (pharmaceutical science) from Shenyang Pharmaceutical University. Dr. Li is mainly engaged in the research, development and commercialisation of nano drugs, and has been responsible for the research and development of more than 20 nano drugs including "Duomeisu" (doxorubicin hydrochloride liposome injection), paclitaxel albumin-bound nano particles and mitoxantrone liposome.

WANG Qingxi
Dr. Wang was appointed as an executive director of the Company in 2018. Dr. Wang is also a director of certain subsidiaries of the Group. Prior to joining the Group, Dr. Wang worked at Merck & Co., Inc. in the U.S. for 20 years where he held senior positions including director of pharmaceutical R&D and director of business development and operation. Dr. Wang holds a bachelor’s degree in science (chemistry) and a master’s degree in science (chemistry) from Nankai University in China, a master’s degree in science (polymer science) and a doctorate in chemistry from University of Connecticut in the U.S. and a MBA degree from Temple University in the U.S..

CHAK Kin Man
Mr. Chak was appointed as an executive director of the Company in 2005. Mr. Chak is also a director of certain subsidiaries of the Group. Mr. Chak is a certified public accountant of the Hong Kong Institute of Certified Public Accountants and a fellow member of the Association of Chartered Certified Accountants. Mr. Chak holds a bachelor of social sciences degree from The University of Hong Kong and has extensive experience in finance, accounting and investor relations.

JIANG Hao
Dr. Jiang joined the Group in August 2020 and is currently the president of finished drug division and senior director of strategic marketing division of the Group. Prior to joining the Group, Dr. Jiang has worked at Fastenal Company as general manager (north and central China) in the U.S., Tianjin Kesun Technology Company (marketing and sales centre of Baidu in Tianjin) as general manager and 3H Health Investment Management Ltd. as assistant to chairman and chief operation officer.

WANG Bo
Mr. Wang was appointed as an independent non-executive director of the Company in 2012. He is also a member of the Audit Committee and Remuneration Committee of the Company. Mr. Wang is currently the CEO of Beijing CHNMED Pharmaceutical Technology Development Co., Ltd and managing director of Beijing CHNMED Pharmaceutical Consulting Co., Ltd.. Mr. Wang graduated from Beijing Institute of Iron and Steel and has extensive experience in pharmaceutical policy research and consulting. Mr. Wang is currently the distinguished researcher of the Research Center of National Drug Policy & Ecosystem.

CHEN Chuan
Mr. Chen was appointed as an independent non-executive director of the Company in 2016. Mr. Chen holds a bachelor’s degree in Medicine from Norman Bethune University of Medical Science and a Master’s degree in Science from Albert Einstein College of Medicine at Yeshiva University.

Mr. Chen is also a director of Beijing Dong Fang Ming Kang Medical Equipment Co., Ltd. (quoted on the National Equities Exchange and Quotations System), a director of Shanghai Benemae Pharmaceutical Corporation (quoted on the National Equities Exchange and Quotations System) and an independent director of Guangxi Liuzhou Pharmaceutical Co., Ltd. (listed on Shanghai Stock Exchange).

WANG Hongguang
Prof. Wang, is a director and professor of International Center for Bioeconomy, Institute of Multidisciplinary Biomedical Research of Tsinghua University (National Institute of Biological Sciences, Beijing). He is also an executive director and adjunct professor of Peking University’s China Center for Strategic Studies, adjunct professor of Tianjin University and China Pharmaceutical University. Prof. Wang has previously served as a director of Center of Biotechnology Development of China of the Ministry of Science and Technology. Prof. Wang has long been engaged in the research on technology and economic strategy, and has conducted in-depth research on domestic and foreign biotechnology development and industry policies. Prof. Wang was the founder of “Disparity Economics” and has published 21 books including “Bio-economic of China” and more than 110 theses. Prof. Wang holds a bachelor’s degree in agriculture from Gansu Agricultural University, a master’s degree in agriculture and a doctorate in agriculture from China Agricultural University. Prof. Wang is currently an independent director of Beijing Tiantan Biological Products Co., Ltd (listed on Shanghai Stock Exchange).

AU Chun Kwok Alan
Mr. Au, is the founder and managing director of GT Healthcare Group, a private equity platform focusing on cross border healthcare investments. Prior to that, Mr. Au served as the head of the Asia Healthcare Investment Banking of Deutsche Bank Group, advising healthcare IPO and M&A in the region, an executive director at JAFCO Asia Investment Group, responsible for healthcare investments in China, and an investment director of Morningside Group in charge of healthcare investments in Asia. Mr. Au received a bachelor’s degree in psychology from Chinese University of Hong Kong and a master’s degree in management from Columbia Business School in New York. Mr. Au is a certified public accountant (CPA) in the U.S. and a chartered financial analyst (CFA), and an associate member of the Hong Kong Institute of Financial Analysts and member of the American Institute of Certified Public Accountants.

Mr. Au is currently an independent director of Cellular BioMedicine Group (Nasdaq: CBMG) and I-Mab Biopharma Co., Ltd. (Nasdaq: IMAB), and a panel member for biotechnology of the Innovation and Technology Fund of the Hong Kong SAR Government.

LAW Cheuk Kin Stephen
Mr. Law was appointed as an independent non-executive director of the Company in 2021. Mr. Law is currently the Managing Director of ANS Capital Limited. He is also an independent non-executive director of China Everbright Limited, Somerley Capital Holdings Limited, China Galaxy Securities Co., Ltd. and Bank of Guizhou Co., Ltd., all of which are listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”). Mr. Law previously served as the Finance Director and a member of the Executive Directorate of MTR Corporation Limited, Chief Financial Officer of Guoco Group Limited, Hong Kong and Managing Director of TPG Growth Capital (Asia) Limited, and held various senior positions in the Morningside Group and Wheelock Group. He was also previously a non-executive director of China NT Pharma Group Limited (listed on the Stock Exchange), an alternate director of MIE Holdings Corporation (listed on the Stock Exchange), an independent non-executive director of AAG Energy Holdings Limited (listed on the Stock Exchange) and Stealth BioTherapeutics Corp. (listed on Nasdaq). He is currently a member of the board of directors of SOW (Asia) Foundation and a council member of Hong Kong Business Accountants Association. He served as a council member of the Hong Kong Institute of Certified Public Accountants from 2010 to 2017 and an adjunct professor of the Hong Kong Polytechnic University from 2015 to 2017. He is currently a member of the Hong Kong Institute of Certified Public Accountants and the Institute of Chartered Accountants in England and Wales. Besides, Mr. Law has been appointed by the Ministry of Finance of the People’s Republic of China as an expert consultant to provide advice on finance and management accounting. Mr. Law holds a Bachelor’s degree in Science (Civil Engineering) from the University of Birmingham, the United Kingdom and received a Master’s degree in Business Administration from the University of Hull, the United Kingdom.

Li Quan
Ms. Li was appointed as an independent non-executive director of the Company in 2022. Ms. Li has over ten years of experience in investment management. She is currently the Managing Director of CDH Investments Management (Hong Kong) Limited, responsible for investment in the healthcare sector in the private equity department. Ms. Li holds a Bachelor of Cell Biology & Genetics and Economics double degree from Peking University, and a Master of Science degree from National University of Singapore School of Computing. She is also a non-executive director of SciClone Pharmaceuticals (Holdings) Limited (stock code: 6600), which is listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”).